FDA‐approved carbonic anhydrase inhibitors reduce amyloid β pathology and improve cognition, by ameliorating cerebrovascular health and glial fitness
Alzheimer's & Dementia · 2023-11 · 19 (11) · 5048-5073
DOI: 10.1002/alz.13063 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 26.04.2023. Verfasst von Elisa Canepa und 13 weiteren Autor:innen. Beteiligte Einrichtung: Alzheimer's Center at Temple, Department of Neural Sciences, Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Cerebral Amyloid Angiopathy, Alzheimer Disease. Die Arbeit wurde bisher 55-mal zitiert (Crossref) und nennt 145 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIA NIH HHS, NINDS NIH HHS.
Abstract (Originalsprache)
Introduction
Cerebrovascular pathology is an early and causal hallmark of Alzheimer's disease (AD), in need of effective therapies.
Methods
Based on the success of our previous in vitro studies, we tested for the first time in a model of AD and cerebral amyloid angiopathy (CAA), the carbonic anhydrase inhibitors (CAIs) methazolamide and acetazolamide, Food and Drug Administration–approved against glaucoma and high‐altitude sickness.
Results
Both CAIs reduced cerebral, vascular, and glial amyloid beta (Aβ) accumulation and caspase activation, diminished gliosis, and ameliorated cognition in TgSwDI mice. The CAIs also improved microvascular fitness and induced protective glial pro‐clearance pathways, resulting in the reduction of Aβ deposition. Notably, we unveiled that the mitochondrial carbonic anhydrase‐VB (CA‐VB) is upregulated in TgSwDI brains, CAA and AD+CAA human subjects, and in endothelial cells upon Aβ treatment. Strikingly, CA‐VB silencing specifically reduces Aβ‐mediated endothelial apoptosis.
Discussion
This work substantiates the potential application of CAIs in clinical trials for AD and CAA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Alzheimer's Center at Temple, Department of Neural Sciences, Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania, USA.
- Department of Neuroscience and Physiology, Neuroscience Institute, NYU Grossman School of Medicine, New York, New York, USA.
- Department on Neurology, Center for Cognitive Neurology, NYU Grossman School of Medicine, New York, New York, USA.
- Department of Pharmaceutical Sciences and Moulder Center for Drug Discovery Research, Temple University School of Pharmacy, Temple University, Philadelphia, Pennsylvania, USA.
- Center of Functionally Integrative Neuroscience (CFIN), Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Förderung
- NIA NIH HHS
- NINDS NIH HHS
Zitieren
APA
Canepa, E., Parodi-Rullan, R., Vazquez-Torres, R., Gamallo-Lana, B., Guzman-Hernandez, R., Lemon, N. L., Angiulli, F., Debure, L., Ilies, M. A., Østergaard, L., Wisniewski, T., Gutiérrez-Jiménez, E., Mar, A. C., & Fossati, S. (2023). FDA‐approved carbonic anhydrase inhibitors reduce amyloid β pathology and improve cognition, by ameliorating cerebrovascular health and glial fitness. Alzheimer's & Dementia, 19(11), 5048-5073. https://doi.org/10.1002/alz.13063
Vancouver
Canepa E, Parodi-Rullan R, Vazquez-Torres R, Gamallo-Lana B, Guzman-Hernandez R, Lemon NL, et al. FDA‐approved carbonic anhydrase inhibitors reduce amyloid β pathology and improve cognition, by ameliorating cerebrovascular health and glial fitness. Alzheimer's & Dementia. 2023;19(11):5048-5073. doi:10.1002/alz.13063
BibTeX
@article{Canepa2023,
author = {Canepa, Elisa and Parodi-Rullan, Rebecca and Vazquez-Torres, Rafael and Gamallo-Lana, Begona and Guzman-Hernandez, Roberto and Lemon, Nicole L and Angiulli, Federica and Debure, Ludovic and Ilies, Marc A and Østergaard, Leif and Wisniewski, Thomas and Gutiérrez-Jiménez, Eugenio and Mar, Adam C and Fossati, Silvia},
title = {FDA‐approved carbonic anhydrase inhibitors reduce amyloid β pathology and improve cognition, by ameliorating cerebrovascular health and glial fitness},
journal = {Alzheimer's & Dementia},
year = {2023},
volume = {19},
number = {11},
pages = {5048--5073},
doi = {10.1002/alz.13063}
}
EUVIMED